Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit

Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit

10.1007/s00262-021-03075-3

Saved in:

Bibliographic Details
Main Authors:	Nickles, Emily, Dharmadhikari, Bhushan, Li, Yating, Walsh, Robert J, Koh, Liang Piu, Poon, Michelle, Tan, Lip Kun, Wang, Ling-Zhi, Ang, Yvonne, Asokumaran, Yugarajah, Chong, Wan Qin, Huang, Yiqing, Loh, Kwok Seng, Tay, Joshua, Soo, Ross, Koh, Mickey, Ho, Liam Pock, Chan, Marieta, Niam, Madelaine, Soh, Melissa, Luah, Yen Hoon, Lim, Chwee Ming, Kaliaperumal, Nivashini, Au, Veonice B, Talib, Najwa Binte Said Nasir, Sng, Reina, Connolly, John E, Goh, Boon Cher, Schwarz, Herbert
Other Authors:	BIOMED INST FOR GLOBAL HEALTH RES & TECH
Format:	Article
Language:	English
Published:	SPRINGER 2023
Subjects:	Science & Technology Life Sciences & Biomedicine Oncology Immunology Nasopharyngeal carcinoma CD137L-DC Dendritic cell immunotherapy EBV Phase 1 clinical trial CD137 LIGAND T-CELLS LYMPHOCYTE-ACTIVATION PHASE-II MONOCYTE IMMUNOTHERAPY RECEPTOR MEMBER DIFFERENTIATION PROLIFERATION
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/239112
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

Description
Summary:	10.1007/s00262-021-03075-3